SCHEMBL3351114

SCHEMBL3351114

O=C(O)NCCC(O)NCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.45
TMEM97 Q5BJF2 2/20 0.45
ALDH1A1 P00352 1/20 0.44
EPHX2 P34913 2/20 0.43
PPARG P37231 2/20 0.43
PPARA Q07869 2/20 0.43
MAPK14 Q16539 1/20 0.43
FFAR1 O14842 1/20 0.43
MTOR P42345 1/20 0.43
LSS P48449 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
PLAAT3 P53816 1/20 0.41
PLAAT5 Q96KN8 1/20 0.41
PLAAT2 Q9NWW9 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3355242 0.84 BCHE (0.49) MAPK14FFAR1MEN1KMT2A
SCHEMBL3350274 0.83 EPHX2 (0.46) EPHX2PPARGPPARAPPARD
SCHEMBL3356473 0.82 SMN1; SMN2 (0.49) ALDH1A1MEN1KMT2ACNR1
SCHEMBL1695141 0.78 MTOR (0.58) KCNH2ALDH1A1EPHX2PPARGPPARA
SCHEMBL16269079 0.78 MTOR (0.51) EPHX2PPARGPPARAMAPK14FFAR1
SCHEMBL3357892 0.78 CASR (0.54) ALDH1A1MEN1KMT2A
SCHEMBL3353131 0.77 MEN1 (0.47) HDAC3HDAC1HDAC2HDAC8MEN1
SCHEMBL2771700 0.76 PLAAT3 (0.64) EPHX2FFAR1HDAC1HDAC8PLAAT3
SCHEMBL3351538 0.74 MAPK14 (0.53) PPARGPPARAMAPK14CNR1PPARD
SCHEMBL6235327 0.72 ALDH1A1 (0.58) KCNH2TMEM97ALDH1A1EPHX2PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP KCNH2 3921/4885TMEM97 2772/4885ALDH1A1 2133/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.